Simulations Plus found with Ticker (SLP) now have a total of 4 analysts covering the stock. The consensus rating is buy. The price target is between 75 and 54 and has an average price target of 59.75. With the previous close at 39.61, this would mean that there is a potential upside of 50.8%. There is a 50-day moving average of 43.45, while the 200-day moving average is 46.63. The company’s market capitalization is $826 million. Visit the company’s website at: https://www.simulations-plus.com
The potential market cap would be $1,246 million based on the market consensus.
You can now share this on Stocktwits, just click on the logo below and paste the ticker into the text to be seen.
Simulations Plus develops drug discovery and development software for modeling, simulation and prediction of molecular properties using artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym and Lixoft. The Company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and simulation products DDDPlus and MembranePlus. It also offers products based on mechanistic and mathematical models such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides absorption, distribution, metabolism, excretion and toxicity prediction for a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products such as MonolixSuite and PKPlus. In addition, it offers contract research services for population modeling and simulation; training and consultancy for accelerating pharmacometric studies; and clinical pharmacology advisory services to support regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetic and food companies, as well as academic and government agencies. Simulations Plus was founded in 1996 and is headquartered in Lancaster, California.